P

    Purple Biotech (PPBT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.76
    +0.08 (+4.76%)

    Market Cap: $2.73M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    58%(19/33)
    Avg Surprise
    -222.67%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-2.88
    Range$-2.88 - $-2.88
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.42+85.4%
    60d ago$-1.73+39.9%
    30d ago$-1.73+39.9%
    7d ago$-1.73+39.9%
    Current$-2.88
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Dec 31, 2026
    EPS Consensus$-1.49
    Range$-1.49 - $-1.49
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.49---
    Sep 26EST
    		-$-2.88---
    Jun 26
    		$1.07$-0.98+209.18%Beat+126.8%
    Mar 26
    		$-2.33$-0.38-512.45%Miss-1261.8%
    Dec 25
    		$-6.16$-3.40-81.18%Miss-127.3%
    Sep 25
    		$2.90$-2.60+211.54%Beat+121.2%
    Jun 25
    		$-4.00$-2.10-90.48%Miss+74.8%
    Mar 25
    		$-0.17$0.00N/ABeat+99.4%
    Dec 24
    		$-2.71$-2.20-23.18%Miss+95.7%
    Sep 24
    		$-13.67$-0.60-2178.33%Miss+67.5%
    Jun 24
    		$-15.88$-26.00+38.92%Beat+64.1%
    Mar 24
    		$-30.26$-30.00-0.87%Miss+27.3%
    Dec 23
    		$-63.14$-34.00-85.71%Miss-7.2%
    Sep 23
    		$-42.02$-44.00+4.50%Beat+7.8%
    Jun 23
    		$-44.22$-50.00+11.56%Beat-22010.0%
    Mar 23
    		$-41.60$-70.00+40.57%Beat-10048.8%
    Dec 22
    		$-58.90$-50.00-17.80%Miss-23460.0%
    Sep 22
    		$-45.56$-42.00-8.48%Miss-26700.0%
    Jun 22
    		$-0.20$-0.20+0.00%Beat-
    Mar 22
    		$-0.41N/AN/ABeat+99.5%
    Dec 21
    		$-0.25N/A+87.50%Beat-2400.0%
    Sep 21
    		$-0.17$-0.01-1600.00%Miss-1600.0%
    Jun 21
    		$0.00N/A+100.00%Beat+100.0%
    Mar 21
    		$-76.00$-2.00-3700.00%Miss-189900.0%
    Dec 20
    		$-0.01$-0.01+0.00%Beat+96.7%
    Sep 20
    		$-0.01$-0.01+0.00%Beat-
    Jun 20
    		$-0.01N/A+90.00%Beat-
    Mar 20
    		$-0.04$0.00N/AMiss+78.9%
    Dec 19
    		$-0.30$-0.09-233.33%Miss+99.0%
    Sep 19
    		$0.00N/A+100.00%Beat-
    Jun 19
    		$0.00N/A+100.00%Beat+100.0%
    Mar 19
    		$-0.19$-0.19+0.00%Beat-90.0%
    Dec 18
    		$-30.00$-20.00-50.00%Miss+0.0%
    Sep 18
    		$0.00N/A+100.00%Beat-
    Jun 18
    		$-0.01N/A+90.00%Beat+99.7%
    Mar 18
    		$-0.10$-0.10+0.00%Beat-
    Dec 17
    		$-30.00$-20.00-50.00%Miss-
    Dec 16
    		$0.00N/A+100.00%Beat-
    Sep 16
    		$-2.90$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.39EV/EBITDA-0.15x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-111.10%ROIC-156.20%
    Financial Health
    Debt/Equity0.01xInterest Coverage-360.69x
    Current Ratio3.70xQuick Ratio3.70x
    Trading Statistics
    Beta-0.54Avg Volume81.01K
    52-Week High$19.4052-Week Low$1.16

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.63
    SMA 20$1.56
    SMA 50$1.55
    SMA 200$4.32
    EMA 10$1.64
    EMA 20$1.59
    EMA 50$1.79
    EMA 200$5.18

    MACD

    Line: 0.03Signal: -0.00Hist: 0.04

    ADX

    ADX: 25.5+DI: 27.2-DI: 11.1

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down32.0
    PSAR$1.52

    Bollinger Bands

    Upper Band$1.75
    Lower Band$1.37
    %B Position2410%(Upper)
    Band Width1.03

    RSI (14-Day)

    Neutral
    63.2

    Momentum Oscillators

    Stoch %K76.1
    Stoch %D77.2
    Williams %R-10.8
    ROC (10d)15.0%
    Momentum0.23
    CCI (20d)142.0
    MFI (14d)78.5

    Volatility Measures

    ATR (14d)$0.13(7.6%)
    StdDev (20d)0.09
    Hist Vol50.3%(High)

    Volume Flow

    VWAP$1.73
    OBV303.5M
    AD Line30.7B
    CMF (20d)0.038

    Volume Metrics

    Avg Vol (20d)78.2K
    Vol Ratio0.2x(Low)
    VWMA (20d)$1.53

    Pivot Points

    R3$1.91
    R2$1.85
    R1$1.77
    Pivot Point$1.71
    S1$1.63
    S2$1.57
    S3$1.49

    Advanced Oscillators

    TSI10.27
    Ultimate Osc53.7
    KST95.47

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of RevenueN/A$64,823$53,331$58,272$48,009$44,766$40,000$49,000$48,999N/A$196$50,000
    Gross ProfitN/A$-64,823$-53,331$-58,272$-48,009$-44,766$-40,000$-49,000$-48,999N/A$-196$-50,000
    Operating Expenses$1.30M$2.25M$23.45M$1.37M$1.24M$1.41M$976,000$2.13M$3.46M$4.47M$6.27M$5.75M
    R&D$702,000$1.23M$1.83M$587,000$553,000$760,000$458,000$1.35M$2.39M$3.42M$5.24M$4.59M
    SG&A$597,000$1.02M$873,000$780,000$683,000$646,000$310,000$785,000$865,000$1.04M$630,000$1.16M
    Operating Income$-1,299,000$-2,251,000$-23,445,000$-1,367,000$-1,236,000$-1,406,000$-1,016,000$-2,133,000$-3,458,000$-4,466,000$-6,267,000$-5,747,000
    Interest Income$79,000$20,000$1,000$123,000$73,000$54,000$152,000$130,000$121,000$702,000$635,000$708,000
    Interest Expense$9,000$31,000$23,000$5,000$0$35,000$511,000$511,000$24,000$17,000$2.59M$16,000
    Income Before Tax$441,000$-89,000$-23,642,000$-1,305,000$-1,089,000$-456,000$-415,000$-668,000$-2,415,000$-3,781,000$-4,859,000$-5,055,000
    Income Tax Expense$0$0$0$0$0$0$0$0$-9,999$683,000$1.21M$689,000
    Net Income$441,000$-86,000$-23,545,000$-1,303,000$-1,085,000$-453,000$-410,000$-663,000$-2,405,000$-3,762,000$-4,828,000$-5,036,000
    EBITDA$520,000$7,000$-23,566,000$-1,242,000$-1,042,000$-376,000$-886,000$-108,000$-2,342,000$-3,716,000$-4,978,000$-4,989,000
    EBIT$450,000$-58,000$-23,619,000$-1,300,000$-1,089,000$-421,000$-926,000$-157,000$-2,391,000$-3,764,000$-5,026,000$-5,039,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PPBT

    News

    Purple Biotech (PPBT) sees 26.5M shares reported owned by broker-dealer group

    G1 Execution Services, LLC and Susquehanna Securities, LLC have jointly reported beneficial ownership of 26,532,000 shares of Purple Biotech Ltd. (PPBT), representing 1.4% of the company's outstanding Ordinary Shares. This information is based on an updated SCHEDULE 13G/A filing, with the ownership calculation derived from 1,864,548,218 shares outstanding as of May 20, 2026. The holdings include American depositary shares (ADSs), where each ADS represents 2,000 Shares, and options to buy ADSs.

    Stock Titan•8/14/26•
    Neutral

    H.C. Wainwright cuts Purple Biotech stock price target on preclinical progress

    H.C. Wainwright has reduced its price target for Purple Biotech Ltd. (NASDAQ:PPBT) to $17.00 from $30.00, while maintaining a Buy rating. This adjustment follows the company's Q2 2026 earnings report and positive preclinical progress for its CAPTN-3 tri-specific T cell engager programs. Despite promising preclinical data, the company faces challenges with cash burn, though it maintains a strong current ratio and more cash than debt.

    Investing.com•8/11/26•
    Neutral

    Purple Biotech (PPBT) highlights CAPTN-3 entry to clinic, CM24 PDAC efficacy and $44B TAM

    Purple Biotech (PPBT) presented an updated corporate presentation highlighting its oncology pipeline, including the CAPTN-3 tri-specific antibody platform with lead asset IM1240 expected to enter human trials in 2027. The company also reported positive Phase 2 data for CM24 in pancreatic ductal adenocarcinoma (PDAC), showing improved response and survival rates. PPBT emphasizes the significant $44 billion total addressable market for IM1240 indications and its cash runway into mid-2027.

    Stock Titan•8/10/26•
    Somewhat-Bullish

    H.C. Wainwright cuts Purple Biotech stock price target on preclinical progress

    H.C. Wainwright has lowered its price target for Purple Biotech Ltd. (NASDAQ:PPBT) to $17.00 from $30.00, while reiterating a Buy rating. This adjustment follows the company's Q2 2026 earnings and corporate update, which included promising preclinical progress for its CAPTN-3 tri-specific T cell engager programs. Despite the target reduction, the revised price still implies a significant upside of nearly 1,100% from the current stock price.

    Investing.com•8/10/26•
    Neutral

    Purple Biotech Reports Second Quarter 2026 Financial Results

    Purple Biotech Ltd. announced its second-quarter 2026 financial results, highlighting positive preclinical data for its IM1240 tri-specific antibody, which is slated for clinical studies in 2027. The company reported a total cash position of $6.1 million, providing a cash runway through mid-2027, and continues to seek strategic collaborations to support clinical advancement. Financial results show a net income of $0.4 million for the quarter, largely due to a non-cash gain from warrant revaluation, despite an operating loss.

    Yahoo Finance Singapore•8/8/26•
    Somewhat-Bullish

    Frequently Asked Questions About PPBT

    Does PPBT pay dividends?
    Purple Biotech (PPBT) does not currently pay a regular dividend.
    What is PPBT's market cap?
    Purple Biotech (PPBT) has a market capitalization of $2.73M with a current stock price of $1.76.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In